NZ792635A - Method of treatment of infection - Google Patents
Method of treatment of infection Download PDFInfo
- Publication number
- NZ792635A NZ792635A NZ792635A NZ79263511A NZ792635A NZ 792635 A NZ792635 A NZ 792635A NZ 792635 A NZ792635 A NZ 792635A NZ 79263511 A NZ79263511 A NZ 79263511A NZ 792635 A NZ792635 A NZ 792635A
- Authority
- NZ
- New Zealand
- Prior art keywords
- composition
- antibiotic
- nsaid
- concentration
- human animal
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims abstract 7
- 238000000034 method Methods 0.000 title claims 16
- 239000000203 mixture Substances 0.000 claims abstract 38
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims abstract 22
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims abstract 22
- 230000003115 biocidal effect Effects 0.000 claims abstract 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract 12
- 239000003795 chemical substances by application Substances 0.000 claims abstract 11
- 230000000813 microbial effect Effects 0.000 claims abstract 6
- 239000003120 macrolide antibiotic agent Substances 0.000 claims abstract 5
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims abstract 4
- 239000002132 β-lactam antibiotic Substances 0.000 claims abstract 4
- 229940124586 β-lactam antibiotics Drugs 0.000 claims abstract 4
- 239000003242 anti bacterial agent Substances 0.000 claims abstract 3
- 210000005075 mammary gland Anatomy 0.000 claims abstract 3
- 239000007972 injectable composition Substances 0.000 claims abstract 2
- 239000003125 aqueous solvent Substances 0.000 claims 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 8
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 6
- 229960000991 ketoprofen Drugs 0.000 claims 6
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims 4
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims 4
- 229960003184 carprofen Drugs 0.000 claims 4
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 claims 4
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 claims 4
- 229960000588 flunixin Drugs 0.000 claims 4
- 229960001929 meloxicam Drugs 0.000 claims 4
- 239000003963 antioxidant agent Substances 0.000 claims 3
- 230000003078 antioxidant effect Effects 0.000 claims 3
- 235000006708 antioxidants Nutrition 0.000 claims 3
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 claims 3
- 235000019375 tylosin Nutrition 0.000 claims 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 claims 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 239000004182 Tylosin Substances 0.000 claims 2
- 229930194936 Tylosin Natural products 0.000 claims 2
- 229940095259 butylated hydroxytoluene Drugs 0.000 claims 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims 2
- 208000004396 mastitis Diseases 0.000 claims 2
- 229960004059 tylosin Drugs 0.000 claims 2
- RXZBMPWDPOLZGW-XMRMVWPWSA-N (E)-roxithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=N/OCOCCOC)/[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 RXZBMPWDPOLZGW-XMRMVWPWSA-N 0.000 claims 1
- AFKRZUUZFWTBCC-WSTZPKSXSA-N 2-(diethylamino)ethyl (2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate Chemical compound N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCCN(CC)CC)C(=O)CC1=CC=CC=C1 AFKRZUUZFWTBCC-WSTZPKSXSA-N 0.000 claims 1
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- UKXFZNMZXWBSGH-UHFFFAOYSA-N Carbomycin A Natural products COC1C(OC2OC(C)C(OC3CC(C)(O)C(OC(=O)CC(C)C)C(C)O3)C(C2O)N(C)C)C(CC=O)CC(C)C(=O)C=CC4OC4CC(C)OC(=O)CC1C(=O)C UKXFZNMZXWBSGH-UHFFFAOYSA-N 0.000 claims 1
- -1 Feracoxib Chemical compound 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 239000004104 Oleandomycin Substances 0.000 claims 1
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 claims 1
- 239000004187 Spiramycin Substances 0.000 claims 1
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 claims 1
- 229940022663 acetate Drugs 0.000 claims 1
- 229960004099 azithromycin Drugs 0.000 claims 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 claims 1
- 229960004217 benzyl alcohol Drugs 0.000 claims 1
- 235000019445 benzyl alcohol Nutrition 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 229960002626 clarithromycin Drugs 0.000 claims 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960004100 dirithromycin Drugs 0.000 claims 1
- WLOHNSSYAXHWNR-NXPDYKKBSA-N dirithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H]2O[C@H](COCCOC)N[C@H]([C@@H]2C)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 WLOHNSSYAXHWNR-NXPDYKKBSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229960004144 josamycin Drugs 0.000 claims 1
- XJSFLOJWULLJQS-NGVXBBESSA-N josamycin Chemical compound CO[C@H]1[C@H](OC(C)=O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](OC(=O)CC(C)C)[C@](C)(O)C2)[C@@H](C)O1 XJSFLOJWULLJQS-NGVXBBESSA-N 0.000 claims 1
- 229950007634 kitasamycin Drugs 0.000 claims 1
- XYJOGTQLTFNMQG-KJHBSLKPSA-N leucomycin V Chemical compound CO[C@H]1[C@H](O)CC(=O)O[C@H](C)C\C=C\C=C\[C@H](O)[C@H](C)C[C@H](CC=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](N(C)C)[C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1 XYJOGTQLTFNMQG-KJHBSLKPSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960002351 oleandomycin Drugs 0.000 claims 1
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 claims 1
- 235000019367 oleandomycin Nutrition 0.000 claims 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 229960000371 rofecoxib Drugs 0.000 claims 1
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 1
- 229960005224 roxithromycin Drugs 0.000 claims 1
- VYGBQXDNOUHIBZ-UHFFFAOYSA-L sodium formaldehyde sulphoxylate Chemical group [Na+].[Na+].O=C.[O-]S[O-] VYGBQXDNOUHIBZ-UHFFFAOYSA-L 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 229960001294 spiramycin Drugs 0.000 claims 1
- 235000019372 spiramycin Nutrition 0.000 claims 1
- 229930191512 spiramycin Natural products 0.000 claims 1
- 229960003250 telithromycin Drugs 0.000 claims 1
- LJVAJPDWBABPEJ-PNUFFHFMSA-N telithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@@H]([C@]2(OC(=O)N(CCCCN3C=C(N=C3)C=3C=NC=CC=3)[C@@H]2[C@@H](C)C(=O)[C@H](C)C[C@@]1(C)OC)C)CC)[C@@H]1O[C@H](C)C[C@H](N(C)C)[C@H]1O LJVAJPDWBABPEJ-PNUFFHFMSA-N 0.000 claims 1
- 229960005041 troleandomycin Drugs 0.000 claims 1
- LQCLVBQBTUVCEQ-QTFUVMRISA-N troleandomycin Chemical compound O1[C@@H](C)[C@H](OC(C)=O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](OC(C)=O)[C@@H](C)C(=O)[C@@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)OC(C)=O)[C@H]1C LQCLVBQBTUVCEQ-QTFUVMRISA-N 0.000 claims 1
- 239000000010 aprotic solvent Substances 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The disclosure relates to an injectable composition for the treatment of a microbial infection in a mammary gland of a non-human animal, wherein the composition includes: (a) a non-steroidal anti-inflammatory drug (NSAID); (b) an antibiotic selected from the group consisting of a beta lactam antibiotic and macrolide antibiotic; (c) a solubilising agent, wherein the solubilising agent has one or more of the following features: i. has a dielectric point above 30 at 25°C ii. has a boiling point above 100°C and/or iii. is a dipolar aprotic solvent; and (d) propylene glycol as a carrier, wherein the amount of propylene glycol in the composition is more than the amount of solubilising agent in the composition; and wherein the NSAID and antibiotic are dissolved in the solubilising agent and propylene glycol.
Claims (30)
1. An injectable composition when used for the treatment of a microbial infection in a mammary gland of a non-human animal, wherein the composition includes a. a non-steroidal anti-inflammatory drug (NSAID); b. an antibiotic selected from the group consisting of a beta lactam antibiotic and macrolide antibiotic; c. a solubilising agent, wherein the solubilising agent comprises a mixture of butylated hydroxytoluene (BHT) and benzyl alcohol and wherein the amount of solubilizing agent is less than 40% w/v; and d. a carrier, wherein the carrier is non-aqueous solvent selected from N-Methyl Pyrrolidone (NMP), dimethyl sulfoxide (DMSO), and dimethylacetamide (DMA); wherein the amount of carrier in the composition is more than the amount of solubilising agent in the composition; and wherein the NSAID and antibiotic are dissolved in the solubilising agent and propylene glycol.
2. The composition as claimed in claim 1 wherein the composition is non-aqueous.
3. The composition as claimed in any one of the above claims wherein the NSAID is selected from Carprofen, Naproxen, Ibuprofen, Ketoprofen, Piroxicam, Diclofenac, Etodolac, Flunixin, Feracoxib, Meloxicam, Celecoxib, Rofecoxib, and combinations thereof.
4. The composition as claimed in any one of the above claims wherein the NSAID is selected from Flunixin, Meloxicam, Carprofen, Ketoprofen and combinations thereof.
5. The composition as claimed in any one of the above claims wherein the NSAID is present at a concentration of 1 – 15% w/v.
6. The composition as claimed in claim 4 wherein the concentration of Flunixin is approximately 7.3 % w/v, the concentration of Meloxicam is approximately 1.0 % w/v, the concentration of Carprofen is approximately 3.0 % w/v or the concentration of Ketoprofen is approximately 4 – 10 % w/v.
7. The composition as claimed in any one of the above claims wherein the macrolide class antibiotic is selected from Azithromycin, Clarithromycin, Dirithromycin, Erythromycin, Roxithromycin, Telithromycin, Carbomycin A, Josamycin, Kitasamycin, Midecamicine/midecamicine acetate, Oleandomycin, Spiramycin, Troleandomycin, and Tylosin/tylocine, and combinations thereof.
8. The composition as claimed in any one of the above claims wherein the macrolide antibiotic is Tylosin.
9. The composition as claimed in any one of the above claims wherein the beta lactam antibiotic is penethamate.
10. The composition as claimed in any one of the above claims wherein the antibiotic is present at a concentration between 10 – 35% w/v.
11. The composition as claimed in any one of the above claims wherein the antibiotic is present at a concentration of approximately 20.0% w/v.
12. The composition as claimed in any one of claims 1 to 11 wherein the ratio of NSAID to antibiotic in the composition is approximately 1:3 w/v.
13. The composition as claimed in any one of the above claims wherein the composition includes at least one anti-oxidant.
14. The composition as claimed in claim 13 wherein the anti-oxidant is selected from sodium formaldehyde sulphoxylate or butylated hydroxyl toluene (BHT), and combinations thereof.
15. The composition as claimed in either claim 13 or 14 wherein the anti-oxidant is present in the composition at a concentration of between 0.01 - 0.3 % w/v.
16. A method of treating a non-human animal for an internal microbial infection wherein there is provided a method of treating a non-human animal for an internal microbial infection characterised by the step of administering a composition as claimed in any one of claims 1 to 15 by injection to the non-human animal.
17. The method as claimed in claim 16 wherein the composition is injected subcutaneously.
18. The method as claimed in claim 16 or 17 wherein the non-human animal is treated with a dosage 5 - 10 milligrams antibiotic per kg of non-human animal per day (mg/kg/day) and 0.2 -4 mg/kg/day of NSAID.
19. The method as claimed in any one of claims 16 to 18 wherein the non-human animal is treated with 5-10 mg/kg/day antibiotic and any one of the following approximate dosages for the NSAID: a. 2.2 mg/kg/day Flunixin b. 0.5 mg/kg/day Meloxicam c. 3 mg/kg/day Ketoprofen d. 1.4 mg/kg/day Carprofen.
20. The method as claimed in any one of claims 16 to 19 wherein the composition is used to treat clinical mastitis and / or early-stage mastitis.
21. A use of a composition substantially as claimed in any of claims 1 to 15 in the manufacture of a medicament for the treatment of a microbial infection.
22. A method of preparing a composition when used for the treatment of a microbial infection in the mammary gland of a non-human animal, containing an NSAID and an antibiotic selected from the group consisting of a macrolide and beta lactam antibiotic characterised by the steps of a) adding at least two non-aqueous solvents to the composition, wherein at least one non-aqueous solvent is a solubilising agent comprising a mixture of butylated hydroxytoluene (BHT) and benzyl alcohol, and at least one non- aqueous solvent is a carrier selected from N-MethylPyrrolidone (NMP), dimethyl sulfoxide (DMSO), and dimethylacetamide (DMA), wherein the amount of carrier is more than the amount of the solubilising agent in the composition.; b) dissolving the NSAID and antibiotic in the at least two non-aqueous solvents.
23. The method as claimed in claim 22 wherein the NSAID in the composition is increased to a concentration (% w/v) which would not be storage stable at room temperature in a corresponding aqueous based composition.
24. The method as claimed in claim 22 or claim 23 wherein the NSAID is Ketoprofen and wherein the concentration of Ketoprofen is above 4% w/v.
25. The method as claimed in any one of claims 22 to 24 wherein the at least two non aqueous solvents are added to a mixing container prior to the addition of either the NSAID or antibiotic.
26. A method as claimed in any one of claims 22 to 25 wherein the carrier is added to the solubilising agent prior to the addition of either the NSAID or antibiotic.
27. A method as claimed in any one of claims 22 to 26 wherein the composition is maintained between 60-80°C until after the NSAID and antibiotic have been substantially dissolved in the at least two non-aqueous solvents.
28. A method as claimed in any one of claims 22 to 27 wherein the antibiotic is added to the at least two non-aqueous solvents and dissolved prior to the addition of the NSAID.
29. A method as claimed in any one of claims 22 to 28 wherein the NSAID is added and dissolved into the mixture of dissolved antibiotic and at least two non-aqueous solvents.
30. A method as claimed in any one of claims 22 to 29 wherein the composition containing the dissolved NSAID and antibiotic is cooled to approximately 30°C before making up to a final volume (qs) with a non-aqueous solvent and mixed for approximately 10 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ792635A NZ792635A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ75310711 | 2011-01-20 | ||
| NZ790013A NZ790013A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
| NZ792635A NZ792635A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ792635A true NZ792635A (en) | 2024-03-22 |
Family
ID=83229130
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ790013A NZ790013A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
| NZ792635A NZ792635A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
| NZ769844A NZ769844A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ790013A NZ790013A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ769844A NZ769844A (en) | 2011-01-20 | 2011-01-20 | Method of treatment of infection |
Country Status (1)
| Country | Link |
|---|---|
| NZ (3) | NZ790013A (en) |
-
2011
- 2011-01-20 NZ NZ790013A patent/NZ790013A/en unknown
- 2011-01-20 NZ NZ792635A patent/NZ792635A/en unknown
- 2011-01-20 NZ NZ769844A patent/NZ769844A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ790013A (en) | 2024-01-26 |
| NZ769844A (en) | 2022-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105267142B (en) | A kind of enrofloxacin injection and preparation method thereof | |
| KR101905173B1 (en) | Injectable compositions for mastitis comprising an NSAID and an antibiotic in a non-aqueous solvent | |
| AU2007332222C1 (en) | Pour on formulation | |
| CN103977017B (en) | A kind of veterinary antiparasitic parenteral solution and preparation method thereof | |
| NZ542379A (en) | Compositions for treating microbial and parasitic infections in cattle and other animals | |
| CN112972379A (en) | Gamithromycin emulsion, preparation method and application in preventing and treating porcine ileitis | |
| CN102973498A (en) | Florfenicol injection and preparation method thereof | |
| CN103006674A (en) | Compound sulfamonomethoxine sodium solution and preparation method thereof | |
| NZ792635A (en) | Method of treatment of infection | |
| NZ792635B2 (en) | Method of treatment of infection | |
| NZ790013B2 (en) | Method of treatment of infection | |
| CN103768014A (en) | Oil injection containing tulathromycin/poloxamer 407 | |
| CN106214632A (en) | A kind of acetaminophen, Diclofenac Sodium Injection and preparation method thereof | |
| CN102018953A (en) | Pharmaceutical composition containing nocathiacin antibiotics | |
| CN108078923A (en) | A kind of florfenicol microemulsion and preparation method thereof | |
| CN103705452A (en) | Antibacterial drug injection containing poloxamer 407 and oily medium | |
| AU2015268626B2 (en) | Injectable compositions for mastitis comprising an NSAID and an antibiotic in a non-aqueous solvent | |
| CN110917128A (en) | Tilmicosin injection | |
| CN103006559A (en) | Doramectin injection and preparation method thereof | |
| Mechesso et al. | Pharmacokinetic parameters and optimal dosage of a florfenicol and tylosin mixture in beagle dogs. | |
| AU2015365533A1 (en) | Injectable formulations of paracetamol | |
| CN104224805A (en) | Compound injection for preventing and treating edema disease of piglet and preparation method of compound injection | |
| WO2010077911A1 (en) | Enema formulations | |
| CN104622799A (en) | Doxycycline injection and preparation method thereof | |
| CN103720645A (en) | Thiocyanate erythromycin injection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |